Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trovafloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 1/20 | 1.00 |
| ▸ | FLT4 | P35916 | 1/20 | 1.00 |
| ▸ | GSK3B | P49841 | 1/20 | 1.00 |
| ▸ | RARB | P10826 | 1/20 | 1.00 |
| ▸ | TBXAS1 | P24557 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 0.90 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.90 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.90 |
| ▸ | HPGD | P15428 | 2/20 | 0.90 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.90 |
| ▸ | POLB | P06746 | 2/20 | 0.90 |
| ▸ | XBP1 | P17861 | 1/20 | 0.90 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.90 |
| ▸ | HTT | P42858 | 1/20 | 0.90 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.90 |
| ▸ | RELA | Q04206 | 1/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | DPP4 | P27487 | 6/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trovafloxacin SCHEMBL1902266 | 1.00 | EPHA2 (1.00) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL34465 | 1.00 | EPHA2 (1.00) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL20769811 | 1.00 | EPHA2 (1.00) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL13575805 | 1.00 | EPHA2 (1.00) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL34466 | 1.00 | EPHA2 (1.00) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL29688441 | 1.00 | EPHA2 (1.00) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL9177464 | 1.00 | EPHA2 (1.00) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL29711175 | 0.99 | EPHA2 (0.98) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL1229029 | 0.99 | EPHA2 (0.98) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL7688504 | 0.99 | EPHA2 (0.98) | EPHA2FLT4GSK3BRARBTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4434588-B1 | AEROSOL DELIVERY DEVICE | PARI PHARMA GMBH (DE) | 2026-04-08 | — | — | EP | claimed |
| EP-3452124-B1 | HEMOSTATIC DEVICES AND METHODS OF USE | MEDTRONIC INC (US) | 2025-10-08 | — | — | EP | claimed |
| EP-3452123-B1 | HEMOSTATIC DEVICES AND METHODS OF USE | MEDTRONIC INC (US) | 2025-09-24 | — | — | EP | claimed |
| EP-3965808-B1 | USE OF PARASITES AND EXTRACELLULAR VESICLES OBTAINED FROM PARASITES IN CANCER TREATMENT | UNIV YEDITEPE (TR) | 2025-09-03 | — | — | EP | claimed |
| EP-4021402-B1 | THIXOTROPIC DELIVERY SYSTEMS | UNIV OF MONTANA (US) | 2025-08-20 | — | — | EP | claimed |
| EP-3976197-B1 | THERAPEUTICS AND METHODS FOR PREDICTING AND OVERCOMING ENDOCRINE RESISTANCE IN BREAST CANCER | LUNELLA BIOTECH INC (CA) | 2025-07-16 | — | — | EP | claimed |
| EP-3230500-B1 | METHODS OF ORIENTING MULTIFILAMENT YARN AND MONOFILAMENTS OF POLY-4-HYDROXYBUTYRATE AND COPOLYMERS THEREOF | TEPHA INC (US) | 2025-06-18 | — | — | EP | claimed |
| EP-4554627-A1 | INHALABLE FORMULATION FOR USE IN THE TREATMENT OF BACTERIAL LUNG INFECTIONS | Solmic Biotech GmbH (DE) | 2025-05-21 | — | — | EP | claimed |
| EP-3711797-B1 | AEROSOL DELIVERY DEVICE | PARI PHARMA GMBH (DE) | 2025-02-12 | — | — | EP | claimed |
| CN-119317433-A | Methods for treating cushing's syndrome and liver disease and reducing hepatotoxicity of other drugs taken by patients | 科赛普特治疗学股份有限公司 | 2025-01-14 | — | — | CN | claimed |
| EP-3122757-B1 | CHARGED LINKERS AND THEIR USES FOR CONJUGATION | HANGZHOU DAC BIOTECH CO LTD (CN) | 2023-09-06 | — | — | EP | claimed |
| EP-4232004-A1 | FRACTAL FORMULATIONS | Nanogyre Sprl (BE) | 2023-08-30 | — | — | EP | claimed |
| EP-3452122-B1 | HEMOSTATIC DEVICES AND METHODS OF USE | MEDTRONIC INC (US) | 2023-03-22 | — | — | EP | claimed |
| EP-3021832-B9 | PRESERVED ETHERIFIED CYCLODEXTRIN DERIVATIVES CONTAINING LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-03-15 | — | — | EP | claimed |
| EP-3337456-B1 | LIPOSOMES WITH GINSENOSIDE AS MEMBRANE MATERIAL AND PREPARATIONS AND USE THEREOF | SHANGHAI GINPOSOME PHARMATECH CO LTD (CN) | 2022-10-26 | — | — | EP | claimed |
| EP-2640393-B1 | CBP/CATENIN ANTAGONISTS FOR ENHANCING ASYMMETRIC DIVISION OF SOMATIC STEM CELLS | UNIV SOUTHERN CALIFORNIA (US) | 2022-10-12 | — | — | EP | claimed |
| EP-3442984-B1 | METHODS FOR DETECTING BORDETELLA | QUEST DIAGNOSTICS INVEST LLC (US) | 2022-08-10 | — | — | EP | claimed |
| EP-3265083-B1 | SUBSTITUTED UREA DEPSIPEPTIDE ANALOGS AS ACTIVATORS OF THE CLPP ENDOPEPTIDASE | ST JUDE CHILDRENS RES HOSPITAL (US) | 2022-07-06 | — | — | EP | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| EP-3067047-B1 | LIPID-BASED COMPOSITIONS OF ANTIINFECTIVES FOR TREATING PULMONARY INFECTIONS | INSMED INC (US) | 2022-04-20 | — | — | EP | claimed |